微創醫療(00853.HK):採納附屬公司購股權計劃
格隆匯2月10日丨微創醫療(00853.HK)宣佈,公司擁有50.47%的附屬公司上海微創醫療機器人(集團)股份有限公司("附屬公司")計劃採納購股權計劃("附屬公司購股權計劃"),以向附屬公司購股權計劃的承授人提供獲取附屬公司所有權權益的機會,此將激勵承授人為提升附屬公司價值而努力工作,並將使公司及其股東整體受益。
附屬公司及其附屬公司主要從事設計、開發及商業化手術機器人,以協助外科醫生完成複雜的外科手術。附屬公司購股權計劃須待(其中包括)公司股東於公司為(其中包括)考慮及酌情批准採納附屬公司購股權計劃而將予召開的股東特別大會上批准後,方可作實。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.